A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab [Avastin (Rm)] and Intravitreal Dexamethasone [Ozurdex (Tm)] for Persistent Diabetic Macular Oedema (SwitchDMO)

Trial Profile

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab [Avastin (Rm)] and Intravitreal Dexamethasone [Ozurdex (Tm)] for Persistent Diabetic Macular Oedema (SwitchDMO)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms SwitchDMO
  • Most Recent Events

    • 05 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 05 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 19 May 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top